Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation
Neoadjuvant therapy has been used for years to treat patients with non-small-cell lung
cancer whose primary tumors are too large to allow for surgery. Reduction in size of the
primary tumor with neoadjuvant therapy has made it possible for those patients. Moreover,
the goals have expanded to include: determination of the sensitivity of the tumor so that
subsequent therapy can be modified accordingly; to prolong disease free survival; to prolong
survival.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective response rate
8 weeks
No
Weimin Mao, MD
Principal Investigator
Zhejiang Cancer Hospital
CFDA: China Food and Drug Administration
BD-IC-IV06
NCT01843647
April 2013
February 2017
Name | Location |
---|